Kingstone Capital Partners Texas LLC Takes $92.39 Million Position in Danaher Corporation $DHR

Key Points

• Kingstone Capital Partners Texas LLC purchased 467,707 shares of Danaher Corporation, valued at approximately $92.39 million, representing about 0.07% of the company's total shares.
• Danaher reported earnings per share (EPS) of $1.80, surpassing analyst expectations, with a quarterly revenue of $5.94 billion, reflecting a 3.4% increase year-over-year.
• The company will pay a quarterly dividend of $0.32 per share on October 31st, with an annualized dividend yield of 0.7%.

Kingstone Capital Partners Texas LLC purchased a new position in Danaher Corporation (NYSE:DHR - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 467,707 shares of the conglomerate's stock, valued at approximately $92,391,000. Kingstone Capital Partners Texas LLC owned about 0.07% of Danaher as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Danaher by 0.4% during the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock worth $12,296,123,000 after purchasing an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock valued at $4,016,404,000 after buying an additional 612,154 shares during the period. Bank of New York Mellon Corp increased its holdings in Danaher by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after buying an additional 194,466 shares during the period. Invesco Ltd. grew its holdings in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Danaher by 4.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate's stock worth $867,168,000 after buying an additional 163,332 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Royal Bank Of Canada set a $241.00 price target on Danaher in a research note on Tuesday, September 2nd. UBS Group decreased their target price on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Barclays reaffirmed an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a research note on Friday, July 11th. Finally, Evercore ISI dropped their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $246.35.

Danaher Price Performance

Shares of NYSE:DHR traded down $1.96 during trading on Friday, reaching $193.31. The company had a trading volume of 5,932,115 shares, compared to its average volume of 3,243,103. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The firm's fifty day moving average is $200.17 and its 200 day moving average is $198.30. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The firm has a market capitalization of $138.42 billion, a PE ratio of 41.13, a price-to-earnings-growth ratio of 2.70 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same quarter in the prior year, the business earned $1.72 EPS. The company's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio is currently 27.23%.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 11.10% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.